Background and Objectives: Dyslipidemia is a family of lipoprotein metabolism disorders manifested by elevated total cholesterol (TC), low-density (LDL-C), triglycerides (TG), reduced high density (HDL-C) concentrations in the blood.[1] was defined according to criteria National Cholesterol Education Program Adult Treatment Panel III. Hypercholesterolemia declared for participants with either ˃...

Objective: To determine the frequency for pattern of dyslipidemia in patients with chronic kidney disease. Study Design: Descriptive, cross-sectional Place and Duration Study: Department Nephrology, Jinnah Postgraduate Medical Centre (JPMC) from 26th December 2018to 28thJune 2019. Methodology: One hundred thirty-two were enrolled. Blood sample 5 ml each patient was taken sent to institutional p...

Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by the U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years older. Its role triglyceride-lowering drug is also emerging literature. However, it not this indication yet, neither adult nor pediatric populati...